Impressive Phase III Results Provides Incentive To Ionis Pharmaceuticals Inc (NASDAQ:IONS),

0
569
Biotech Stock News

Ionis Pharmaceuticals Inc (NASDAQ:IONS), one of the Top Biotech Stocks, made an announcement about some positive results that had been obtained from the pivotal phase III study. The study targeted persons suffering from familial chylomicronemia syndrome (FCS). APPROACH is the other name for the above study.

Lately, Ionis Pharma has been performing terribly and that is pretty clear simply by the look at the underperformance of its shares recently. The significant underperformance witnessed at Zacks classified Medical-Drugs industry was one of the major drops it has ever witnessed. A lot of its top officials are finding difficulties accepting that its shares dropped by 2.8% whereas the industry gained a whole 7%.

The study used about 66 patients, all of them with FCS.A t the end of it all, it was able to meet its primary end points and the 77% reduction demonstration in the number of triglycerides of volanesorsen-treated patients (n=33) gathered from the baseline within a period of three months was surprising for anyone considering the 18% increase in the placebo-treated patients (n=33) .It took a 52—week treatment duration to actually tell the treatment was effective.

The health provider is looking forward to filing a marketing authorization for FCS  in Canada, The U.S and Europe. Additionally, Akcea is currently undertaking some two more phase III studies of volanesorsen – COMPASS and BROADEN.

BROADEN is the same condition that goes by the name familial partial lipodystrophy (FPL) and it is ongoing at the moment and by 2019 its data might be released. The company has gotten itself involved in a lot of activities which it has been doing the best way possible. For instance the COMPASS study for persons with triglycerides above 500 mg/dL has been happening and of course its success will be a step forward in health and wellness sector. In the year 2016, the COMPASS research proudly made the announcement about the study meeting up the primary endpoint.

With a lot of research going on in most of the leading organization, the Biotech Stock News might soon have something important to report on!

LEAVE A REPLY

Please enter your comment!
Please enter your name here